Nature5d
Denileukin diftitox—a step towards a 'magic bullet' for CTCL
In addition to cytotoxic CD8 + cells, CD4 + T REG cells have recently been implicated in antitumor response. Their presence in the skin infiltrates of mycosis fungoides has been correlated with a ...
Everyday Health24d
What Is T-Cell Lymphoma?
The specific treatment course and prognosis for T-cell lymphoma depends on the subtype — of which there are many — and how advanced the cancer is. Hodgkin lymphoma involves a type of cancer ...
Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...
Fierce Biotech11d
Sanofi pays $600M upfront for Dren Bio's bispecific in latest immunology play
In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...
Pharmabiz11d
Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan
Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...